Overview
Efficacy of Dexamethasone for Prevent Vomiting in Leukemic Children Who Receive Intrathecal Chemotherapy
Status:
Completed
Completed
Trial end date:
2011-12-01
2011-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Null hypothesis The proportions of vomiting are not different between dexamethasone and placebo in the patient after sedation with intravenous ketamine and lumbar puncture with intrathecal chemotherapy Alternative hypothesis The proportions of vomiting are different between dexamethasone and placebo in the patient after sedation with intravenous ketamine and lumbar puncture with intrathecal chemotherapyPhase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
CHANCHAI TRAIVAREETreatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Ketamine
Criteria
Inclusion Criteria:- Patients aged between 2-15 years who underlying acute lymphoid or nonlymphoid leukemia
and need to receive ketamine and intrathecal chemotherapy.
- Personally signed and dated informed consent and assent document indicating that the
subject (or legally acceptable representative) has been informed of all pertinent
aspects of the trial prior to study entry.
Exclusion Criteria:
- Patients who had a known allergy to ketamine or dexamethasone.
- Patients who had contraindication for ketamine or dexemethasone such as hypertension,
increased intracranial pressure or central nervous system mass lesion, major
psychiatric , and hyperglycemia.
- Patients who concurrent with nausea and vomiting during that time.
- Patients who received ondansetron or other antiemetic before doing Procedure.
- Patients who received other chemotherapy before or after 24 hours.